FDA upping drug inspections in China; Mylan sues Celgene for blocking generics;

@FiercePharma: Trending on FierceVaccines: GSK will tailor vaccine portfolio, improve access as part of wider Africa initiative. More | Follow @FiercePharma

@TracyStaton: Still best-read FiercePharma: It's a big win for Eli Lilly in multibillion-dollar Alimta patent fight. Story | Follow @TracyStaton

@EricPFierce: RT: Last year, my sister died, and I learned firsthand about life sciences' limits. Article from FierceMedicalDevices | Follow @EricPFierce

@CarlyHFierce: Amgen, GSK part on fast-selling Prolia, mostly. More | Follow @CarlyHFierce

> The FDA is increasing its inspections of drugs in China, the top official there testified Thursday. Story

> Mylan ($MYL) has sued Celgene ($CELG) for its efforts to keep generics of Revlimid and Thalomid off the market. Report

> Arkansas Attorney General Dustin McDaniel says he's asking the state Supreme Court to reconsider its decision to toss out a $1.2 billion judgment against Johnson & Johnson ($JNJ) over the marketing of the antipsychotic drug Risperdal. Story

> Vermont is requiring doctors to conduct a risk assessment before prescribing Zogenix's ($ZGNX) controversial new high-powered painkiller Zohydro. More

> Pharmaceutical companies paid healthcare professionals in the U.K. a total of £38.5 million last year for speaking at healthcare conferences, down slightly from the year before. Story

Medical Device News

@FierceMedDev: J&J gets a mixed verdict in a trial alleging it sold faulty vaginal mesh implants. More | Follow @FierceMedDev

@MarkHFierce: ICYMI: Biotronik may have a relatively small U.S. mkt share, but it is working hard to compete here. Story | Follow @MarkHFierce

@MichaelGFierce: The year in nanotech drug delivery. Special report | Follow @MichaelGFierce

@EmilyWFierce: Adhesive medical sensors with origami-like wires could flex and bend with the skin, say researchers at Northwestern University. News | Follow @EmilyWFierce

> RefleXion raises $11.6M in Series A funding round. More

> Holaira brings in $42M Series D to test COPD lung denervation treatment tool. Article

> Vapotherm seals $24M financing round, elects new board member. Story

Biotech News

@FierceBiotech: For those of you just waking up and getting to work in the U.S., here's our second issue of EuroBiotech: Read | Follow @FierceBiotech

@JohnCFierce: Amgen down 1.7%. I'm going to start calling Amgen a pharma co. If it walks like a duck... | Follow @JohnCFierce

@DamianFierce: Amgen: T-Vec hits on durable response but misses on OS, its secondary endpoint. Release | Follow @DamianFierce

@EmilyMFierce: The current environment for cancer care in Europe: Infographic via Janssen | Follow @EmilyMFierce

> AbbVie gets out of the way as the EU prepares for trial transparency. More

> Merck and Ferring team up on anti-bleeding drug for the developing world. News

> GTx's CEO finds the door as the company moves on from a PhIII failure. Article

And Finally... FDA Commissioner Margaret Hamburg expects her agency's proposal on e-cigarette regulation to be ready for release "very soon." More

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.